Results 61 to 70 of about 10,236,148 (357)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Parkinson's Disease, 2015
Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating
Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti   +6 more
doaj   +1 more source

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

Molecules, 2017
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is ...
Monique Hoon, Jacobus P. Petzer, Francois Viljoen, Anél Petzer   +3 more
doaj   +1 more source

Pramipexole in comparison to l-dopa: a neuropsychological study

, 2003
Twenty right-handed patients affected by early/mild Parkinson's disease were evaluated in a randomised study using neuropsychological and clinical assessements during three treatment modalities: when in the off treatment condition, when on pramipexole ...
Pierantozzi, M, Peppe, A, Brusa, L, Stanzione, P, Stefani, A, Ruggieri, S, Caramia, M, STEFANI, ALESSANDRO, PIERANTOZZI, MARIANGELA, Boffa, L, STANZIONE, PAOLO, Bassi, A   +11 more
core   +1 more source

mGluR5 in ECCCK to BLA Circuit Modulates Depressive‐Like Phenotypes through CCK Signaling

Advanced Science, EarlyView.
Dysregulation of mGluR5 and CCK signaling contributes to major depressive disorder, yet circuit‐level mechanisms remain unclear. Here, the ECCCK→BLA pathway is identified as a critical regulator of affective behavior. mGluR5 modulates synaptic function and CCK signaling within this circuit, controlling stress susceptibility and depressive‐like states ...
Muhammad Asim, Huajie Wang, Gao Qianqian, Abdul Waris, Jufang He   +4 more
wiley   +1 more source

DNA‐mimic for Specific Surface Functionalization of Zr‐MOFs for Bacterial Targeting

Angewandte Chemie, EarlyView.
We introduce phosphotyrosine‐modified PNA as a superior, single‐step post‐synthesis surface coating for PCN‐222. The DNA mimic allows for controlled post‐functionalization with single‐stranded DNA for the attachment of protein moieties for bacterial targeting. ABSTRACT Nanosized metal–organic frameworks (MOFs) are versatile platforms used in biomedical
Anna Scheeder, Jon Ostolaza‐Paraiso, Andrew G. Baker, Juan F. Blandez, Georgina E. Lindop, Simon M. Fairclough, Ljiljana Fruk, Ioanna Mela, David Fairen‐Jimenez, Clemens F. Kaminski   +9 more
wiley   +2 more sources

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain

Parkinson's Disease, 2012
Astrocyte endfeet surround brain blood vessels and can play a role in the delivery of therapeutic drugs for Parkinson’s disease. However, there is no previous evidence of the presence of LAT transporter for L-DOPA in brain astrocytes except in culture ...
M. Y. Inyushin, A. Huertas, Y. V. Kucheryavykh, L. Y. Kucheryavykh, V. Tsydzik, P. Sanabria, M. J. Eaton, S. N. Skatchkov, L. V. Rojas, W. D. Wessinger   +9 more
doaj   +1 more source

Effects of Subchronic Treatment With Selegiline on L-DOPA-Induced Increase in Extracellular Dopamine Level in Rat Striatum

Journal of Pharmacological Sciences, 2006
.: Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p.
Adachi Kouichi, Miwa Hideto, Kusumoto Haruko, Shimazu Seiichiro, Kondo Tomoyoshi   +4 more
doaj   +1 more source

Serum L-DOPA levels.

, 2015
(A) Time-course of serum L-DOPA levels after last L-DOPA administration at dose 5 mg/kg (day 10) with co-injection of 1.25 mg/kg carbidopa (n = 5 per AAV2-hAADC or AAV2-GFP group) and without carbidopa co-injection (n = 5 per AAV2-hAADC or AAV2-GFP group)
Nitasha Sharma (720396), Agnieszka Ciesielska (720395), John Forsayeth (195320), Krystof Bankiewicz (568946), Janine Beyer (195280)   +4 more
core   +1 more source

SERS Facemask for Rapid and Portable Sensing Mycobacterium Tuberculosis Antigens for TB Screening

Advanced Science, EarlyView.
Our study introduced an Au─Ag embedded covalent organic framework (U@COF) ‐mediated facemask for sensing TB antigen ESAT‐6/CFP‐10 complex in clinical droplet samples toward TB screening. Practical analysis of clinical samples demonstrated the availability of our facemask, which is capable of identifying the TB subjects (N = 17) from healthy candidates (
Lingzhi Chen, Jiaqi Yu, Jing Xu, Lingqi Chen, Ninghao Zhang, Wenrui Li, Runmin Zeng, Xiaomin Luo, Yiqun Chang, Jiayin Lai, Wenshi Huang, Xiaochen Liang, Ting Zhao, Shanze Chen, Huaihong Cai, Yanguang Cong, Pinghua Sun, Jiang Pi, Xueqin Huang, Haibo Zhou, Junxia Zheng   +20 more
wiley   +1 more source

The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats

Molecules
The use of phosphodiesterase inhibitors in the treatment of Parkinson’s disease is currently widely discussed. The study aimed to investigate the impact of acute and chronic treatment with the phosphodiesterase 5 inhibitor, sildenafil, at low and ...
Elżbieta Lorenc-Koci, Kinga Kamińska, Tomasz Lenda, Jolanta Konieczny   +3 more
doaj   +1 more source